Targeting HLA-DR.
Tay
Kevin
K
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Dunleavy
Kieron
K
Wilson
Wyndham H
WH
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D019540:Area Under Curve; D005221:Fatigue / Q000139:chemically induced; D005334:Fever / Q000139:chemically induced; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism; D008657:Metabolic Clearance Rate; D017202:Myocardial Ischemia / Q000139:chemically induced; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006684:HLA-DR Antigens; C448699:apolizumab